The expression of TROY, E-cadherin, and vimentin in tumor samples obtained from nine NSCLC patients who were resistant to the first-generation EGFR-TKI and without T790M mutation were determined by immunohistochemistry staining (Figures 7A,B). This evidence concerns the gene TNFRSF19 and neoplasm.